bpc-157 clinical evidence safety human trial trials oral vs injection The hype around a new class Is BPC‑157 a Risk? Safety, – Dr. - TLDR: BPC-157 has

In September 2023, FDA placed "Thymosin Beta-4, Fragment (LKKTETQ)," the substance sold as TB-500, on Category 2 of its interim 503A bulk drug substances list, meaning FDA identified significant safety concerns and would not permit licensed compounding pharmacies to use it

For a patient who wants to start their elimination protocol this week rather than next month, that turnaround changes the timeline meaningfully

It is often explored in chronic infection and wound-healing protocols

Liu H, Xu X, Li J, Liu Z, Xiong Y, Yue M, Liu P

Dosing (research context) : Often reported in the 200500 mcg daily range , though protocols vary